The information contained on this web page is only a summary of the information presented in more detail in the Notice of (I) Pendency of Class Action and Proposed Settlement; (II) Settlement Hearing; and (III) Motion for an Award of Attorneys’ Fees and Litigation Expenses (the “Notice”), which you can access by clicking here.  Since this web page is just a summary, you should review the Notice for additional details.

The Parties have reached a settlement of this action for $130,000,000 in cash (the “Settlement”) for the benefit of the Settlement Class (defined below). On November 17, 2021, the Court held a hearing on final approval of the Settlement and related matters and announced that it would approve the Settlement. On November 22, 2021, the Court entered a Judgment finally approving the Settlement and orders approving the proposed Plan of Allocation for the proceeds of the Settlement and awarding attorney's fees and litigation expenses to Plaintiffs’ Counsel.

If you are a member of the Settlement Class, you are subject to the Settlement and you may be eligible for a payment from the Settlement. The Settlement Class consists of the following three subclasses: 

(1) as to claims arising under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ("Exchange Act"), all persons and entities who purchased or otherwise acquired Allergan plc (before June 15, 2015, known as Actavis plc) common and/or preferred stock between October 29, 2013 and November 2, 2016, both dates inclusive, and were damaged thereby;

(2) as to claims arising under Section 14(a) of the Exchange Act in connection with the merger between Actavis plc and Forest Laboratories, Inc. (i.e., Forest Merger), all persons and entities who held Forest common stock as of May 2, 2014, and were entitled to vote on the Forest Merger, and acquired shares of Allergan common stock in the Forest Merger and were damaged thereby; and

(3) as to claims arising under Section 14(a) of the Exchange Act in connection with the merger between Actavis plc and Allergan, Inc. (i.e., Actavis Merger), all persons and entities who held Allergan, Inc. common stock as of January 22, 2015, and were entitled to vote on the Actavis Merger, and acquired shares of Allergan common stock in the Actavis Merger and were damaged thereby.            

Excluded from the Settlement Class are certain persons and entities who are excluded by definition (see paragraph 29 of the Notice) or who requested exclusion from the Settlement Class.

If you are a member of the Settlement Class, in order to be potentially eligible for a payment from the Settlement, you must submit a Claim Form postmarked (if mailed) or online (using this website), together with adequate supporting documentation, no later than December 27, 2021.

Payments to eligible claimants will be made only after any appeals are resolved, and after the completion of all claims processing. Please be patient, as this process will take some time to complete.

If you have questions, you may call the Allergen Securities Litigation Help Line at  1-877-777-9328 or email info@AllerganDrugPricingSecuritiesLitigation.com.